Top drug regulator is retiring as FDA departures mount

Top career officials have been rapidly leaving the agency, with some choosing to take early retirements and others being forced out.

June 23, 2025 Check out STAT+

Sponsored By

Last chance: Today is the final day to get 50% off your first year of STAT+. Don't miss this deal, and thanks for reading.

Jose Luis Magana/AP STAT+ | Top drug regulator is retiring as FDA departures mount Jacqueline Corrigan-Curay, who runs a key FDA center, is the latest top official to depart the agency. By Lizzy Lawrence STAT+ | Novo Nordisk ends deal with Hims due to compounding concerns with obesity drugs Novo alleges that Hims has been engaging in "illegal mass compounding" of GLP-1 obesity treatments and "deceptive marketing." By Elaine Chen STAT+ | FDA chief's goals of 'radical transparency' threatened by agency cuts FDA cuts gutted key conflict of interest staff, raising concerns about transparency, advisory panel delays, and drug oversight under the new commissioner. By Lizzy Lawrence Andrew Harnik/Getty Images STAT+ | Senate Republicans discuss new way to cut Medicaid in Trump's tax bill Key Republican senators are discussing a provision that would sharply limit federal spending on the Affordable Care Act's Medicaid expansion. By Daniel Payne STAT+ | Amgen's obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing The results that the company's decision to use a slower dosing schedule to make the drug more tolerable in further testing. By Elaine Chen STAT+ | Compass psilocybin therapy shown to be effective in largest-ever study in depression Single dose of psychedelic drug led to a mean reduction of 3.6 points on standard measure of clinical depression with no safety issues raised By Olivia Goldhill Steven Senne/AP Opinion: The Senate's version of Trump's tax-cut bill threatens safety-net hospitals like ours While the House One Big Beautiful Bill preserves vital existing Medicaid financing, the Senate bill would have the opposite effect. By Esmaeil Porsa and Christine Alexander Opinion: The decades-long journey to Gilead's twice-a-year HIV prevention drug lenacapavir "It looks like an alien molecule": How scientists created Gilead's new HIV prevention drug lencapavir, or Yeztugo. By William Pao

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser